Effects of omalizumab on markers of inflammation in patients with allergic asthma

@article{Holgate2009EffectsOO,
  title={Effects of omalizumab on markers of inflammation in patients with allergic asthma},
  author={Stephen T Holgate and Nicola Smith and Marc Massanari and Pablo Jimenez},
  journal={Allergy},
  year={2009},
  volume={64}
}
Asthma is a chronic inflammatory disease of the airways in which immunoglobulin E (IgE) plays a key role by activating a variety of inflammatory cells through interactions with FcɛRI and FcɛRII receptors. The role of IgE in allergic inflammation provided the rationale for developing omalizumab, a humanized monoclonal anti‐IgE antibody, for patients with moderate‐to‐severe or severe allergic asthma. The reductions in circulating levels of IgE resulting from omalizumab treatment leads to… 

An Overview of the Effects of anti-IgE Therapies

  • A. Yalcin
  • Biology, Medicine
    Medical science monitor : international medical journal of experimental and clinical research
  • 2014
Omalizumab in patients with severe persistent asthma (SPA) was an effective therapy for asthma and the following co-morbid conditions: chronic urticaria (CU), bee venom allergy, latex allergy, atopic dermatitis, food allergy and Samter’s syndrome.

Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial

Anti-IgE therapy with omalizumab decreases levels of cytokines that are involved in Th2 polarization and allergic inflammation, including TSLP, TARC and OX40L, according to the SCORAD system.

Omalizumab for pediatric asthma

Omalizumab is of proven efficacy in adults and children with severe asthma and allows a markedly reduced dependence on oral and inhaled corticosteroids and decreased hospitalizations.

Omalizumab is effective and available for treatment of patients with severe allergic asthma in Poland.

Patients with severe allergic asthma who are aged 12 years or older and who have positive skin prick test results or in vitro re‐ activity to perennial aeroallergens, may be treated with omalizumab within the national treatment program of the Polish National Health Fund.

Omalizumab in Children

The aim of the present review is to assess all applications of omalizumab as therapy in the pediatric population and the approved indications—allergic asthma and CSU—are reviewed.

Update on optimal use of omalizumab in management of asthma

Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions, therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.

Higher levels of soluble Fas ligand and transforming growth factor-β after omalizumab treatment: a case report.

Anti-IgE Therapy

The propensity to develop an exaggerated antibody response to inhaled antigens operated by immunoglobulin E (IgE), which is defined as atopy, plays a central role in the pathobiology of allergic

ANTI-Ige: An Overview

A genome-wide association study identified a previously unknown asthma-susceptibility locus on chromosome 17q21, harboring the adjacent genes ORMDL3 (ORMDL sphingolipid biosynthesis regulator 3) and GSDMB (Gasdermin B), which has been confirmed in ethnically diverse populations, and gene–environment interactions have been detected between susceptibility alleles and exposure to cigarette smoke and furred pets.

Anti-IgE – emerging opportunities for Omalizumab

This review aims to look at the various randomised and non-randomised clinical trials, case series and case reports for the role of Omalizumab in conditions other than asthma.
...

References

SHOWING 1-10 OF 63 REFERENCES

The effect of omalizumab on nasal allergic inflammation.

The clinical benefit of treatment with omalizumab is associated with an anti-inflammatory effect on cellular markers in blood and nasal tissue.

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

The lack of effect of omalizumab on methacholine responsiveness suggests that IgE or eosinophils may not be causally linked to airway hyperresponsiveness to Methacholine in mild to moderate asthma.

Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells.

  • Yu‐Ching HuangB. LeykoM. Frieri
  • Medicine, Biology
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2005

Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab

It is suggested that omalizumab has potential as a novel treatment for allergic asthma and circulating levels of inflammatory mediators and clinical symptoms in patients with moderate to severe allergic asthma decreased.

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.

Anti-IgE therapy reduces leukotriene release of peripheral leukocytes stimulated with allergen in children with allergic rhinitis undergoing allergenic immunotherapy independent of the type of SIT allerGEN used.

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.

Basophil Histamine Release Decreases during Omalizumab Therapy in Allergic Asthmatics

Maximal histamine release and cellular sensitivity to the allergen were significantly decreased in the omalizumab group compared to placebo, accompanied by significant changes in the clinical markers airway resistance, β-agonist usage, skin prick test wheal area and investigator ratings of global evaluation of treatment effectiveness.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use.
...